Brain Tumour Biobank

Certification Status: Approved
Registration Status: Completed
Objective:

The Brain Tumour Biobank is committed to collecting, processing, and disseminating high-quality samples and information, encompassing a spectrum from benign tumours to aggressive forms like glioblastoma. Rigorously approved and audited by an independent human research ethics committee in line with the ethical standards set by the National Health and Medical Research Council, this initiative not only amplifies the utility of samples but also accelerates research findings, potentially transforming outcomes for brain tumour patients. The Brain Tumour Biobank is also a NSW Health Pathology certified biobank, meaning its processes and procedures are certified as in line with international best practices including ISO 20387 – Biotechnology – Biobanking – General Requirement for biobanking. Brain tumours, exhibiting diverse cell origins and behaviors, span from benign to aggressive, with glioblastoma posing a particularly challenging treatment landscape and enduring stagnant survival rates over the past 35 years. Despite current treatments such as surgery, radiotherapy, and chemotherapy, the outlook for aggressive brain cancers remains disheartening. In the pursuit of advancing brain cancer research, the biobank aspires to forge new collaborations with researchers, driving progress in risk identification, early detection, sub-classification, and the discovery of innovative treatments.

Registered Biobank Name Brain Tumour Biobank (BTB)
Biobank Leader Peter Truong
Principal Investigator Dr. Peter Truong
Address 442 Botany Rd
Beaconsfield, NSW, Australia
Website https://www.charlieteofoundation.org.au/
Email for biobank inquiries research@charlieteofoundation.org.au
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.
Biospecimen Collected: